AzTrials
AzTrials

Neurogenic BowelCP342NCT05381610

A Clinical Investigation Evaluating Peristeen® Performance

A study testing Peristeen in people with Neurogenic Bowel, run by Coloplast A/S at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Peristeen has been on the market globally since 2006 and marketed in the US since 2012, and more than 10,000 patients worldwide have been using Peristeen, with over 3,000 patients in the US. However, the US reimbursement is not uniform, resulting in many patients suffering from NBD in sub-optimal bowel manage-ment. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Neurogenic Bowel
What is being tested?
Peristeen
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
6 participants
Where
1 siteUnited States
Study dates
1 Jun 2022to 13 Feb 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Have given written informed consent
  • Be diagnosed with neurogenic bowel dysfunction (NBD), plus:
  • Neurogenic bowel dysfunction score (Appendix A) of 10 or higher, indicating moderate or severe NBD AND
  • Documented failure to achieve adequate bowel management in the last 30-days using the standards of care regimen including medications that alter GI transit but is naïve* to LVE and Peristeen
  • NOTE: For this study only, subjects are required to be naive for statistical analyses purposes.
  • For Spinal Cord Injury Subjects Only: Is past or outside initial spinal cord shock window
Show all 12Show fewer
  • Be at least 18 years of age and have full legal capacity
  • Be willing and able to comply with investigation procedures - includes ability to forgo any rectal stimulation, rectal therapies or rectally administered medications or treatments for the duration of the study
  • Have a normal digital examination on file in the past 6 months.
  • Anorectal manometry test and data on file within past 6 months.
  • Successful balloon expulsion test on file within the past 6 months. (i.e., can expel the balloon in 120 seconds or less)
  • In the opinion of the investigator, be an appropriate candidate for the study

Who cannot join

  • Have history/episode of severe autonomic dysreflexia, bradycardia or tachycardia.
  • History of bowel perforation
  • Have known anal or colorectal stenosis
  • Have active/recurrent colorectal cancer
  • Have active inflammatory bowel disease and/or Crohn's disease
  • Any of the following anal conditions: Anal fissure, anal fistula or third- or fourth-degree haemorrhoids
Show all 21Show fewer
  • Have any history of irradiation therapy or chemotherapy targeting the abdomen and/or pelvic region
  • Have any history of gastrointestinal, anal, and/or colorectal surgery (i.e., appendectomy, tubal ligation or hysterectomy, hemorrhoidectomy, cholecystectomy, and/or hiatal hernia surgery, LARS, MACE)
  • Be within 4 weeks of endoscopic polypectomy (includes biopsy and/or endoscopy)
  • Have an implanted stimulation device of any kind.
  • Have ischemic colitis
  • Have chronic or complex diverticular disease (i.e., acute, severe, ulcerative, previous and/or abscess)
  • Have history of colonic obstruction, structural diseases of the colon or ileus
  • Are pregnant, planning on becoming pregnant, or breastfeeding
  • Have known phthalate sensitivity, specifically dibutyl phthalate
  • Are current user of Peristeen or Large Volume Enemas
  • Chronically used Peristeen or Large Volume Enema in the past 2 years.
  • Diagnosis of opioid-induced constipation and/or narcotic bowel syndrome.
  • Have severe Cognitive or severe physical impairment that prevents the ability to administer Peristeen by themselves and/or lack of caregiver support to administer Peristeen administration.
  • Have other individual factors, in the opinion of the physician/healthcare professional, in which participating is contraindicated.
  • Participation in concomitant clinical trial.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Atrium Health

    Charlotte, North Carolina, 28204

Other trials in United States

About this study

Official title: A Clinical Investigation Evaluating Peristeen® Performance Characteristics of Scintigraphic Measurements in Patients With Neurogenic Bowel Dysfunction

Peristeen has been on the market globally since 2006 and marketed in the US since 2012, and more than 10,000 patients worldwide have been using Peristeen, with over 3,000 patients in the US. However, the US reimbursement is not uniform, resulting in many patients suffering from NBD in sub-optimal bowel manage-ment. Therefore, this study will scientifically define and describe how the Peristeen system is different from a large volume enema.

Read the detailed description

The Peristeen system is a non-surgical, FDA-cleared, Class II device for the treatment of patients with neu-rogenic bowel dysfunction (NBD) who have failed conservative bowel management treatment and would otherwise be considered candidates for surgery. (Note: The Peristeen pump with connectors and tubing only is considered to be a FDA class I device. When associated with the rectal balloon catheters, the Peristeen system is considered a class II device thereby giving the entire System an overall designation of class II.) The Peristeen system is a non-surgical, manual system, consisting of a control unit (featuring a pneumatic bulb pump and a four-position rotary switch), a water bag (featuring a pressure relief valve), tubes and con-nectors up to a lubricated catheter which is inserted into the anal canal to allow water to enter the bowel. The system is also accompanied by straps to secure the system on the thigh while being used. The Peristeen catheter is equipped with a balloon which may be inflated or deflated with air once positioned in the rectum. Peristeen has been on the market globally since 2006 and marketed in the US since 2012. More than 10,000 patients worldwide have been using Peristeen, with over 3,000 patients in the U.S (United States).

Neurogenic Bowel Dysfunction (NBD) as defined by the American Academy of Physical Medicine and Re-habilitation, is an, "impairment of the gastrointestinal and anorectal function from a lesion in the nervous system." These neurological lesions can come from a range of disease states, such as, but not limited to spina bifida, multiple sclerosis, Parkinson's, and Spinal Cord Injury (SCI) . Numerous publications and findings have been conducted in humans using Peristeen, with over 120 publications in just the past 5 years.

As a result of the inability to evacuate the bowel, NBD patients experience fecal constipation, fecal impaction, and/or a failure to contain stool in the bowel (i.e., fecal incontinence). These defecation disturbances can be severe enough that they can increase a patient's risk for repeated emergency care. The prevalence of NBD is well documented and occurs in both children and adults. For example, not only do these constipation issues prevail in children and young adults with spina bifida, approximately one third of the NBD patients are fecally incontinent. These resulting complications with bowel management results in an increased risk for urinary tract infections (UTIs), due to the anatomical proximity of the bowel and lower urinary tract. Specific to SCI patients, literature reports that 95% require more than one intervention to initiate defecation.

Quality of life for this patient population has been observed to decline as the severity of NBD increases and patients with SCI report that bowel dysfunction has a greater negative impact on life than any other SCI-related impairment with approximately 50% reporting moderate-to-severe NBD symptoms. The symptoms of NBD and the inability to management their bowels can cause significant emotional distress, affecting self-esteem, personal relationships, and social life.

The time required for bowel management is also a factor of a NBD patient's life. Many patients with NBD spend a significant part of their day on bowel management with 14% to 63% spending more than 1 hour on each episode. Furthermore, complete assistance from a care giver is required by 23% and some help is required by 12%. Peristeen's ergonomic design, leg strap, pump mechanism, inflatable balloon, makes it possible for immobilized patients or those with poor hand function to conduct the procedure them-selves, thereby allowing for personal independence and privacy/discreteness.

Peristeen is differentiated from standard bowel care and its clinical superiority and cost-effectiveness have been clearly demonstrated in patients with NBD. An analysis of real-life data in N = 227 NBD patients who have failed standard bowel care (SBC) and has found that Peristeen can reduce the stoma surgery rate by 64% in the first 2 years after treatment initiation and 35% over a lifetime. Specifically, the 2-year stoma surgery rate for Peristeen vs. standard bowel care is 2% vs. 6%, respectively. Furthermore, in a human clinical trial, N = 49; MS patients showed a decrease in hospitalizations of 41% per year when patients use Peristeen. Without Peristeen, the physical issues that arise result in an increase in healthcare utilization. For example, adults with NBD have been shown to be more than twice as likely to be admitted to the hospital due to fecal impaction and constipation in comparison to healthy individuals. If not managed properly, NBD can ultimately lead to stoma surgery or need for permanent residential care.

Despite the documented clinical success with Peristeen, it is marginally accessible due in large part to a misclassification as a large volume enema (LVE). Typically, LVE is an over-the-counter product that consists of a water bag or bladder, tubing with adjustable clamp to connect and start/stop the gravity-fed water flow to the rectal catheters/probe, and a hook or ability to hang the bag. As gravity is used to administer and adjust the flow of water into the rectum, the patient typically needs assistance and/or needs to lay on the floor near the toilet to administer. Peristeen has an adjustable/inflatable balloon catheter to allow for a complete seal in the rectum where LVEs do not, thereby allowing patients to sit on the toilet or commode during the process. The leg strap and ergonomic dial and pump also allow the patient to perform the procedure independently.

Treatments like LVE are noted to be difficult to retain fluid in patients as there is no secure way to seal the rectum, thus much of the fluid involuntarily flowing out during installation. In addition, published literature characterizing the quantity of fecal removal with LVE is lacking and is an uncommon use in practice, thus, there is no understanding of how well they fully empty the colon. In Spinal Cord Injury patients, bowel distension caused by LVEs has been reported to trigger autonomic dysreflexia. Thus, the purpose of this study will be to investigate and compare the effects of both a large-volume enema and Peristeen on emptying of the colon.

Being tested
Peristeen
Medical subject headings
Neurogenic Bowel

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PeristeenDevice

    The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.

Study groups in NCT05381610
Study groupRoleWhat they receive
Neurogenic BowelExperimentalThis is a US-Only, early feasibility, Investigational Device Exemption - Non-Significant Risk (IDE-NSR), single-center, open label study evaluating the effects of Peristeen, compared to a LVE administered into the rectum. The subjects to be analysed will be subjects with : Neurogenic Bowel Dysfunction (NBD). The NBD cohort will be broken down into two phases: LVE and Peristeen. See Statistical section 10 for more infor-mation on cohort and sub-group analyses.
Receives: Device: Peristeen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The differences in the scintigraphy images, i.e. percentage of fecal matter, will be compared between the LVE and Peristeen.

    The subject's fecal matter movement will be measured radiologically and the percent changes in both a large-volume enema and Peristeen treatment will be measured.

    Measured: 72 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2022
  2. Study start1 Jun 2022
  3. Primary completion1 Jan 2024
  4. Study completion13 Feb 2024

Why it stopped: Lack of enrollment - Sponsor decision

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05381610
Sponsor's protocol ID
CP342
Acronym
CP342
Status last verified
Apr 2023
First submitted
14 Mar 2022
Last updated
15 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Peristeen in people with Neurogenic Bowel, run by Coloplast A/S at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 15 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Lack of enrollment - Sponsor decision). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The differences in the scintigraphy images, i.e. percentage of fecal matter, will be compared between the LVE and Peristeen. (time frame: 72 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in